The DPP8 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human NCI-H1299 lung adenocarcinoma cell line, featuring targeted disruption of the DPP8 gene. This heterogeneous cell pool provides a stable loss-of-function model for studying dipeptidyl peptidase 8 biology without the limitations of transient silencing. Suitable for advanced research, it enables investigation of DPP8-dependent processes in a cancer-relevant context.
The parental NCI-H1299 line was established from a lymph node metastasis of a lung carcinoma in a 43-year-old male and is widely employed as a model for non-small cell lung cancer (NSCLC) metastasis. These epithelial cells recapitulate key metastatic features, including migratory capacity and resistance to apoptosis, making them an appropriate host for examining DPP8??s roles in tumor progression and immune modulation.
DPP8 is a serine dipeptidyl peptidase activated by interferon-gamma and cytokines, functioning as a critical regulator of the NLRP1 inflammasome. It interacts directly with NLRP1 and the adaptor ASC to control caspase-1 activation, which in turn processes pro-IL-1?? and pro-IL-18 into mature inflammatory cytokines, triggering pyroptosis. DPP8 also cleaves substrates such as NPY and GLP-1 and influences chemokine expression. In DPP8-deficient NCI-H1299 cells, the absence of catalytic activity disrupts this signaling axis, leading to dysregulated inflammasome output and altered cytokine secretion, with consequences for both intrinsic apoptosis and extracellular immune signaling.
In the context of lung adenocarcinoma, DPP8 knockout is poised to perturb the balance between cell survival and inflammatory cell death. Dysregulated NLRP1 inflammasome activation may promote pyroptosis, releasing IL-1?? and IL-18 into the tumor microenvironment and potentially reshaping anti-tumor immunity. Simultaneously, altered apoptosis pathways could affect tumor cell proliferation and metastatic potential. This model thus facilitates dissection of the dichotomous roles of pyroptosis in cancer, where it can either foster inflammation-driven progression or enhance immune-mediated clearance.
Research applications include target validation for DPP8 inhibitors using IL-1?? ELISA and caspase-1 activity assays, as well as mechanistic studies of inflammasome components via western blotting and RT-qPCR. Functional assays for viability, apoptosis, and migration link molecular changes to cellular phenotypes relevant to NSCLC. Co?culture systems with immune cells can be employed to examine DPP8-dependent modulation of the tumor microenvironment. For detailed protocols, validation datasets, or personalized support, please contact Ascent Research.
